MX2018015254A - Neurotoxinas botulinicas modificadas. - Google Patents

Neurotoxinas botulinicas modificadas.

Info

Publication number
MX2018015254A
MX2018015254A MX2018015254A MX2018015254A MX2018015254A MX 2018015254 A MX2018015254 A MX 2018015254A MX 2018015254 A MX2018015254 A MX 2018015254A MX 2018015254 A MX2018015254 A MX 2018015254A MX 2018015254 A MX2018015254 A MX 2018015254A
Authority
MX
Mexico
Prior art keywords
disclosed
substitution mutations
botulinum neurotoxins
receptor binding
serotype
Prior art date
Application number
MX2018015254A
Other languages
English (en)
Inventor
Dong Min
Stenmark Paul
Zhang Sicai
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of MX2018015254A publication Critical patent/MX2018015254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)

Abstract

Se describen polipeptidos modificados de la neurotoxina Clostridial Botulinum (BoNT) con un dominio de union al receptor modificado del serotipo B (BoNT/B) Clostridial Botulinum, que comprende una o mas mutaciones de sustitucion en las posiciones correspondientes a 1248 o 1249 en el serotipo B, cepa 1; las mutaciones de sustitucion especifica incluyen I1248F, I1248Y, I1248H, I1248W, V1249W, V1249F, V1249Y, V1249H, I1248W/V1249F, I1248W/V1249Y, I1248W/V1249H, I1248F/V1249Y, I1248F/V1249H, I1248Y/V1249H, I1248F/V1249W, I1248Y/V1249W, I1248H/V1249W, I1248Y/V1249F, I1248H/V1249F, o I1248H/V1249Y; tambien se describen otras mutaciones de sustitucion; tambien se describen los dominios de union al receptor modificado aislado, las moleculas quimericas, las composiciones farmaceuticas y los metodos de uso de las mismas.
MX2018015254A 2016-06-08 2017-06-08 Neurotoxinas botulinicas modificadas. MX2018015254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347579P 2016-06-08 2016-06-08
PCT/US2017/036628 WO2017214447A1 (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Publications (1)

Publication Number Publication Date
MX2018015254A true MX2018015254A (es) 2019-08-16

Family

ID=59227906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015254A MX2018015254A (es) 2016-06-08 2017-06-08 Neurotoxinas botulinicas modificadas.

Country Status (13)

Country Link
US (1) US11104891B2 (es)
EP (1) EP3468985A1 (es)
JP (2) JP7152392B2 (es)
KR (1) KR20190025906A (es)
CN (1) CN109476713A (es)
AU (1) AU2017277905B2 (es)
BR (1) BR112018075363A2 (es)
CA (1) CA3026492A1 (es)
EA (1) EA201892784A1 (es)
IL (1) IL263058B2 (es)
MX (1) MX2018015254A (es)
SG (2) SG11201810210UA (es)
WO (1) WO2017214447A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2854840T (pt) 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
HUE057258T2 (hu) * 2015-03-26 2022-05-28 Harvard College Szerkesztett Botulinum neurotoxin
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
MX2018014066A (es) * 2016-05-16 2019-04-04 Harvard College Metodo para purificacion y activacion de la neurotoxina botulinica.
MX2019000151A (es) * 2016-07-08 2019-08-29 Childrens Medical Center Una neurotoxina botulinica novedosa y sus derivados.
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
US20210040467A1 (en) 2018-01-30 2021-02-11 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
CN114957482A (zh) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途
KR20230001260A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230001254A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
WO2023068485A1 (ko) * 2021-10-22 2023-04-27 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물
CA3234608A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
KR20240051355A (ko) * 2022-10-12 2024-04-22 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
NZ569541A (en) * 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US8273865B2 (en) * 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
PT2854840T (pt) 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
WO2016149404A1 (en) 2015-03-16 2016-09-22 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
JP7152392B2 (ja) 2022-10-12
IL263058B1 (en) 2023-07-01
AU2017277905A1 (en) 2018-12-20
BR112018075363A2 (pt) 2019-03-19
AU2017277905B2 (en) 2022-04-14
CA3026492A1 (en) 2017-12-14
EA201892784A1 (ru) 2019-05-31
US20190300869A1 (en) 2019-10-03
KR20190025906A (ko) 2019-03-12
JP2022112031A (ja) 2022-08-01
SG11201810210UA (en) 2018-12-28
SG10201912099TA (en) 2020-02-27
IL263058A (en) 2018-12-31
IL263058B2 (en) 2023-11-01
WO2017214447A1 (en) 2017-12-14
US11104891B2 (en) 2021-08-31
JP2019523015A (ja) 2019-08-22
CN109476713A (zh) 2019-03-15
EP3468985A1 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
MX2018015254A (es) Neurotoxinas botulinicas modificadas.
NZ702310A (en) Engineered botulinum neurotoxin
MX2019000151A (es) Una neurotoxina botulinica novedosa y sus derivados.
WO2019067815A3 (en) A neurotoxin-like toxin and uses thereof
JOP20190291A1 (ar) جزيئات جسم مضاد ضد cd73 واستخداماتها
AU2018256592A1 (en) Binding proteins comprising at least two repeat domains against HER2
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MX2018002183A (es) Composiciones y metodos para tratamiento del dolor.
NZ756763A (en) Engineered transferrin receptor binding polypeptides
MX2016010360A (es) Moleculas de anticuerpo para el virus del dengue y uso de las mismas.
MX2016003945A (es) Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias.
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
NZ725568A (en) Modified j-chain
SA518400443B1 (ar) طريقة لتنقية وتنشيط السم العصبي الوشيقية
WO2009008916A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2024202396A1 (en) Lactase enzymes with improved properties
EP3592374A4 (en) STRAIN OF BACILLUS AMYLOLICFACIENS GF423, AND COMPOSITION HAVING ANTI-OXIDIZING AND ANTI-INFLAMMATORY ACTIVITIES OR PREVENTING OR TREATING HYPERLIPIDEMIA, INCLUDING A POLYPEPTIDE PRODUCED THEREOF
PH12020551270A1 (en) Botulinum neurotoxin biohybrid
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
MX2021000307A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
MX2018016282A (es) Proteasas asparticas.
GB202103372D0 (en) Modified clostridial neurotoxins
MX2022016591A (es) Moléculas de anticuerpo contra april y usos de las mismas.
周稳 et al. Progress in the Bacillus laccase